---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-058513"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:59:47.178052+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio discloses supplemental proxy details to resolve merger-related shareholder lawsuits

## Summary
- Two federal lawsuits filed in CA and DE allege proxy omissions on LENZ financials, advisor conflicts; 12 additional demand letters received.
- Company voluntarily adds disclosures including Transaction Committee member compensation ($0 extra) and liquidation value of $2.86/sh in Feb 2024.
- Liquidation analysis per share in March 2027: $0.10 low case, $0.19 high case based on $5.6M-$11.1M net cash.
- Leerink DCF analysis yielded implied exchange ratio range of 2.8075-3.2957, valuing LENZ equity at $460M-$540M.
- Graphite denies allegations, states proxy complies with law; no executive officers expected to serve in combined company post-merger.

## SEC filing metadata
- accession: 0001193125-24-058513
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000119312524058513/0001193125-24-058513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000119312524058513/d772578d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-058513
- JSON: https://secwatch.observer/filing/0001193125-24-058513.json
- Plain text: https://secwatch.observer/filing/0001193125-24-058513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.